About
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity.
In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study in patients with severe lung injury.
A global Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with a top-line data readout targeted for the second half of 2024.
Funding history · 6 rounds · $90.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Chemomab Therapeutics complete its merger with Anchiano Therapeutics?
- Chemomab Therapeutics completed its merger with Anchiano Therapeutics in March 2021.
- What was the outcome of Chemomab's Phase 2 trial for CM-101 in Primary Sclerosing Cholangitis, announced in July 2024?
- In July 2024, Chemomab Therapeutics announced positive Phase 2 trial results for CM-101 in Primary Sclerosing Cholangitis, achieving primary and secondary endpoints by demonstrating anti-fibrotic, anti-inflammatory, and anti-cholestatic effects.
- What was the result of Chemomab's Phase 2a liver fibrosis biomarker trial in NASH patients, reported in January 2023?
- In January 2023, Chemomab reported top-line results from its CM-101 Phase 2a liver fibrosis biomarker trial in NASH patients.
- What significant regulatory designation did Chemomab Therapeutics receive for CM-101 in November 2023?
- In November 2023, Chemomab Therapeutics received FDA Fast Track Designation for CM-101 for the treatment of Primary Sclerosing Cholangitis.
- When did Chemomab Therapeutics complete patient enrollment for its CM-101 Phase 2 Primary Sclerosing Cholangitis trial?
- Chemomab Therapeutics announced the completion of patient enrollment in its CM-101 Phase 2 Primary Sclerosing Cholangitis trial in January 2024, moving up the expected top-line readout to mid-year 2024.
- What was the outcome of Chemomab's End-of-Phase 2 meeting with the FDA regarding Nebokitug (CM-101) in Primary Sclerosing Cholangitis, as announced in February 2025?
- In February 2025, Chemomab completed a successful End-of-Phase 2 meeting and aligned with the FDA on a clear and efficient path to potential regulatory approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis.
- What was the total amount raised by Chemomab Therapeutics through its various funding rounds?
- Chemomab Therapeutics has raised a total of $90,500,000 USD through its funding rounds.
- Which investors participated in Chemomab Therapeutics' $10 million private placement in July 2024?
- In July 2024, OrbiMed, Sphera Global Healthcare Fund, and HBM Healthcare Investments participated in Chemomab Therapeutics' $10 million private placement.
- When did Chemomab Therapeutics become a public company on NASDAQ?
- Chemomab Therapeutics became a public company on NASDAQ in March 2021.